Calithera Biosciences (CALA) Reports Q2 Net Loss of $9.1M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. AMZN
2. INTC
3. COIN
4. RDDT
5. PINS
6. FSLR
7. SYK
8. DASH
9. FND
10. GILD

Go back to Calithera Biosciences (CALA) Reports Q2 Net Loss of $9.1M

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

August 15, 2022 4:05 PM EDT

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.

We continue to deliver on our commitment to efficiently advance our clinical programs, successfully initiating two new clinical trials and sharing program updates at two important medical conferences, said Susan Molineaux, PhD, president and chief executive officer of Calithera. We look forward to sharing data from the ongoing mivavotinib and sapanisertib phase 2 trials by the first quarter of 2023, as well as providing an... More